Compare · ABT vs PHAT
ABT vs PHAT
Side-by-side comparison of Abbott Laboratories (ABT) and Phathom Pharmaceuticals Inc. (PHAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PHAT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $158.63B, about 196.3x PHAT ($807.9M).
- Over the past year, ABT is down 32.0% and PHAT is up 13.1% - PHAT leads by 45.1 points.
- PHAT has been more active in the news (11 items in the past 4 weeks vs 6 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 11 for PHAT).
- Company
- Abbott Laboratories
- Phathom Pharmaceuticals Inc.
- Price
- $90.69-0.41%
- $10.01-1.28%
- Market cap
- $158.63B
- $807.9M
- 1M return
- +4.29%
- -18.29%
- 1Y return
- -32.01%
- +13.11%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 6
- 11
- Recent ratings
- 25
- 11
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest PHAT
- Director Parikh Asit received a gift of 28,000 shares and gifted 28,000 shares, decreasing direct ownership by 54% to 24,122 units (SEC Form 4)
- Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
- Director Parikh Asit was granted 24,122 shares and exercised 17,500 shares at a strike of $4.95, increasing direct ownership by 396% to 52,122 units (SEC Form 4)
- Director Fields Heidi was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)
- Director Topper James N was granted 24,122 shares, increasing direct ownership by 57% to 66,718 units (SEC Form 4)
- Director Stenhouse Mark was granted 24,122 shares, increasing direct ownership by 80% to 54,122 units (SEC Form 4)
- Director Schroeder Theodore R was granted 24,122 shares, increasing direct ownership by 115% to 45,122 units (SEC Form 4)
- Director Cola Michael F was granted 24,122 shares, increasing direct ownership by 61% to 63,920 units (SEC Form 4)
- Director Karbe Frank was granted 24,122 shares, increasing direct ownership by 36% to 91,622 units (SEC Form 4)
- SEC Form 8-K filed by Phathom Pharmaceuticals Inc.